A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Eisai Inc
- 29 Jan 2019 Status changed from recruiting to discontinued.
- 24 Apr 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 New trial record